Objectives: We sought to investigate whether the previously reported midterm clinical benefit
of planned sirolimus-eluting stent (SES) implantation in patients with ST-segment elevation …

To the Editor: Because patients with acute ST-segment elevation myocardial infarction
(STEMI) were excluded from early randomized trials, only relatively short-term data from …

BACKGROUND: The Multicentre Evaluation of Single high-dose Bolus TiRofiban versus
Abciximab with Sirolimus-eluting Stent or Bare Metal Stent in Acute Myocardial Infarction …

Context Abciximab infusion and uncoated-stent implantation is a complementary treatment
strategy to reduce major adverse cardiac events in patients undergoing angioplasty for ST …

ContextBare-metal stenting with abciximab pretreatment is currently considered a
reasonable reperfusion strategy for acute ST-segment elevation myocardial infarction …

Background Two placebo-controlled trials testing intravenous platelet glycoprotein IIb/IIIa
antagonists in the setting of percutaneous coronary revascularisation with intracoronary …

Objectives: The aim of this study was to investigate whether the reported favorable 1-year
outcome of the sirolimus-eluting stent (SES) versus the bare-metal stent (BMS) in the …

BACKGROUND: Drug-eluting stent (DES) may offer benefits in terms of repeat
revascularization, which may be counterbalanced by a potential higher risk of stent …

Aims Compared with placebo, abciximab has been associated with mortality reduction at
late follow-up. The TARGET trial was performed to test whether tirofiban and abciximab …

Objectives: The goal of this study was to demonstrate superiority of sirolimus-eluting stents
(SES) over bare-metal stents (BMS) and of abciximab over no abciximab in primary …